• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性硬化症的病程。对1976年至1980年间102例多发性硬化症患者进行的前瞻性研究的初步结果。

Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976-1980.

作者信息

Patzold U, Pocklington P R

出版信息

Acta Neurol Scand. 1982 Apr;65(4):248-66. doi: 10.1111/j.1600-0404.1982.tb03084.x.

DOI:10.1111/j.1600-0404.1982.tb03084.x
PMID:7102254
Abstract

The course of multiple sclerosis was monitored by means of a long-term prospective study. This paper reports on first results from this study, covering 102 patients who were monitored for 2 years or more and examined regularly. It is attempted to quantify the extent of the worsening or improvement in the patients' clinical status over the period of observation using regression analysis techniques. The severity of the disease did not correlate to the period of observation in 15% of the cases, these displaying no progression with regard to the clinical signs. In most cases (32%) a description of the disease progression was possible by means of a linear regression line, 21% had a parabolic and 23.5% an increasingly progressive course. For nine patients a second or third degree polynomial regression curve could be used to describe the course of the disease. The individual progression of the disease as estimated using the linear regression coefficient did not correlate with the individual relapse rate (on average 1.1 per year), nor with the age of the patient, the severity of the multiple sclerosis, the duration of the illness or with the previous course of the disease.

摘要

通过一项长期前瞻性研究对多发性硬化症的病程进行了监测。本文报告了该研究的初步结果,涵盖了102例被监测2年或更长时间并定期接受检查的患者。试图使用回归分析技术量化观察期内患者临床状态恶化或改善的程度。在15%的病例中,疾病严重程度与观察期无关,这些病例在临床体征方面没有进展。在大多数病例(32%)中,可以通过线性回归线描述疾病进展,21%呈抛物线形,23.5%呈逐渐进展的病程。对于9例患者,可以使用二次或三次多项式回归曲线来描述疾病病程。使用线性回归系数估计的疾病个体进展与个体复发率(平均每年1.1次)、患者年龄、多发性硬化症的严重程度、病程或既往疾病病程均无相关性。

相似文献

1
Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976-1980.多发性硬化症的病程。对1976年至1980年间102例多发性硬化症患者进行的前瞻性研究的初步结果。
Acta Neurol Scand. 1982 Apr;65(4):248-66. doi: 10.1111/j.1600-0404.1982.tb03084.x.
2
Mitoxantrone: a review of its use in multiple sclerosis.米托蒽醌:其在多发性硬化症中的应用综述
CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010.
3
Distribution of disease courses in familial vs sporadic multiple sclerosis.家族性与散发性多发性硬化疾病病程分布。
Acta Neurol Scand. 2019 Mar;139(3):231-237. doi: 10.1111/ane.13044. Epub 2018 Dec 3.
4
Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis.临床孤立综合征、复发缓解型和继发进展型多发性硬化症患者的长期随访
Mult Scler. 2003 Jun;9(3):260-74. doi: 10.1191/1352458503ms914oa.
5
Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study.多发性硬化症的长期和短期预后:一项为期3年的随访研究。
Arch Neurol. 1996 Apr;53(4):353-8. doi: 10.1001/archneur.1996.00550040093018.
6
Azathioprine in multiple sclerosis--a 3 year controlled study of its effectiveness.硫唑嘌呤治疗多发性硬化症——一项关于其疗效的3年对照研究
J Neurol. 1980;223(2):97-117. doi: 10.1007/BF00313173.
7
Clinical course of multiple sclerosis: A nationwide cohort study.多发性硬化症的临床病程:一项全国性队列研究。
Mult Scler. 2017 Oct;23(11):1488-1495. doi: 10.1177/1352458516681197. Epub 2016 Dec 12.
8
Natural history of multiple sclerosis: a unifying concept.多发性硬化症的自然史:一个统一的概念。
Brain. 2006 Mar;129(Pt 3):606-16. doi: 10.1093/brain/awl007. Epub 2006 Jan 16.
9
Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.光学相干断层扫描测量的视网膜厚度与多发性硬化症残疾恶化风险:一项队列研究。
Lancet Neurol. 2016 May;15(6):574-84. doi: 10.1016/S1474-4422(16)00068-5. Epub 2016 Mar 18.
10
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.大麻素用于进行性炎症性脑病(CUPID)试验:一项随机双盲安慰剂对照平行组多中心试验及大麻素延缓多发性硬化症进展的经济学评估。
Health Technol Assess. 2015 Feb;19(12):vii-viii, xxv-xxxi, 1-187. doi: 10.3310/hta19120.

引用本文的文献

1
Cost-Consequence Analysis of Natalizumab Compared with Other High-Efficacy Treatments in Patients with Relapsing-Remitting Multiple Sclerosis.那他珠单抗与其他高效治疗方法用于复发缓解型多发性硬化症患者的成本-后果分析
Pharmacoeconomics. 2025 Sep 18. doi: 10.1007/s40273-025-01539-3.
2
Cost-effectiveness of ofatumumab for the treatment of relapsing forms of multiple sclerosis in the United Arab Emirates.奥法木单抗治疗阿联酋复发型多发性硬化症的成本效益
Ther Adv Neurol Disord. 2025 Apr 28;18:17562864251330260. doi: 10.1177/17562864251330260. eCollection 2025.
3
Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study.
natalizumab早期使用与延迟使用在高度活动性复发缓解型多发性硬化症中的成本-后果分析:一项模拟研究
J Neurol. 2025 Jan 17;272(2):153. doi: 10.1007/s00415-024-12723-4.
4
Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis.奥瑞珠单抗治疗伊朗复发型多发性硬化症患者的成本效益
Curr J Neurol. 2021 Jul 6;20(3):154-161. doi: 10.18502/cjn.v20i3.7691.
5
Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada.在加拿大,用奥法妥木单抗治疗复发缓解型多发性硬化症的成本-后果分析。
J Comp Eff Res. 2023 Sep;12(9):e220175. doi: 10.57264/cer-2022-0175. Epub 2023 Aug 22.
6
Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal.奥瑞珠单抗治疗葡萄牙复发型和原发进展型多发性硬化症的成本效益分析。
Pharmacoecon Open. 2023 Mar;7(2):229-241. doi: 10.1007/s41669-022-00381-z. Epub 2022 Dec 1.
7
Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada.奥法木单抗治疗加拿大复发缓解型多发性硬化症的成本效益分析。
Pharmacoecon Open. 2022 Nov;6(6):859-870. doi: 10.1007/s41669-022-00363-1. Epub 2022 Sep 15.
8
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland.在瑞士,与干扰素β-1a 相比,西尼莫德治疗活动性疾病的成人继发进展型多发性硬化的成本效果和预算影响。
Pharmacoeconomics. 2021 May;39(5):563-577. doi: 10.1007/s40273-021-01023-8. Epub 2021 Apr 1.
9
Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy.在意大利,对复发缓解型多发性硬化症中升级使用那他珠单抗或免疫调节剂之间转换的成本效果分析。
BMC Health Serv Res. 2019 Jun 28;19(1):436. doi: 10.1186/s12913-019-4264-1.
10
Multiple sclerosis.多发性硬化症。
Nat Rev Dis Primers. 2018 Nov 8;4(1):43. doi: 10.1038/s41572-018-0041-4.